Five papers worth your time — May 21, 2026
NEJM published no new original research for a third consecutive day; JAMA family and BMJ lead today's indexing window. Five entries: tocilizumab (IL-6 blocker) reaches 54% remission in biomarker-selected treatment-resistant depression (NNT=5, JAMA Psychiatry proof-of-concept RCT); 69-trial BMJ meta-analysis of 153K patients delivers high-certainty evidence that calcium and vitamin D do not prevent fractures; LOSE-AF finds ~10% weight loss doesn't reduce AF symptoms in older patients; county-level structural racism independently predicts a 34% 2-year lung cancer survival gap (n=54,344); and a Danish registry of 379K individuals reassures that isotretinoin in adolescence is not associated with clinically meaningful height reduction.
The JAMA family and the BMJ led today's indexing window. NEJM published no new original research articles (three consecutive days), and the Lancet group is quiet ahead of its next issue. The five entries below span psychiatry, preventive medicine, cardiology, oncology health equity, and dermatology — with two directly challenging current standard-of-care assumptions.
1. An arthritis drug reaches 54% remission in treatment-resistant depression — NNT=5
Journal: JAMA Psychiatry (IF ~25) · Double-blind placebo-controlled proof-of-concept RCT · Published online May 20, 2026 · DOI 10.1001/jamapsychiatry.2026.10531
Study design: Single-center RCT at Cambridge, UK (2018–2022). Thirty adults with moderate-to-severe depression, documented poor antidepressant response, and low-grade systemic inflammation (high-sensitivity C-reactive protein ≥0.3 mg/dL on two separate tests plus a Beck Depression Inventory II somatic subscale score ≥7) were randomized to a single intravenous infusion of tocilizumab 8 mg/kg (max 800 mg; n=14) vs. normal saline (n=16). Tocilizumab (trade name: RoActemra/Actemra) is an IL-6 receptor antagonist approved for rheumatoid arthritis. Follow-up ran to day 28; 29 of 30 completed.
Key results:
- Remission at day 28: 53.9% (7/13) tocilizumab vs. 31.3% (5/16) placebo — NNT=51
- Response rate: 46.2% vs. 18.8% — NNT=42
- No results reached statistical significance (expected at n=30 — the trial was powered as a proof-of-concept, not a confirmatory study)
- Treatment effects fell within clinically meaningful ranges across depression severity, fatigue, anxiety, and quality of life measures1
- The largest effects appeared at day 28 (final assessment), suggesting stepwise improvement over time
- No serious adverse events; no withdrawals
- Baseline hs-CRP — not IL-6 itself — tracked depression improvement, suggesting hs-CRP may be the more practical predictor for patient selection
For comparison: the NNT for SSRIs in unselected depression populations is approximately 7.
Peer-review status: Published in JAMA Psychiatry; fully peer-reviewed. Funded by Wellcome, NIHR Bristol Biomedical Research Centre, NIHR Cambridge BRC, and BMA Foundation. First trial to use IL-6 receptor blockade as a psychiatric treatment target with biomarker-guided patient selection (ISRCTN16942542).
Author affiliation: Lead author Dr. Éimear Foley (Senior Research Associate, University of Bristol); senior author Prof. Golam Khandakar (Professor of Psychiatry and Immunology, University of Bristol).
"Our study moves us closer to more tailored depression care, where treatments are chosen to better fit a person's biology."— Dr. Éimear Foley, University of Bristol1
Clinical implication: Depression affects 10–20% of people at some point in their lives; a meaningful fraction don't respond adequately to sequential antidepressants. This is one of the first RCTs to test immunotherapy for depression and the first to demonstrate that targeting IL-6R with a biomarker-screened population can outperform placebo by a margin that exceeds SSRI benchmarks on NNT. The trial is small and underpowered for significance — replication in a larger multi-site confirmatory RCT is essential before clinical use. Still, hs-CRP ≥0.3 mg/dL is a routinely available lab value; if larger trials hold, patient selection for immunotherapy would be straightforward in most outpatient settings.
2. 69 RCTs, 153K patients: calcium and vitamin D supplements do not prevent fractures
Journal: The BMJ (IF ~107) · Systematic review and meta-analysis · Published online May 20, 2026 · DOI 10.1136/bmj-2025-0880503
Study design: Systematic review and meta-analysis of 69 randomized controlled trials enrolling 153,902 adults. Three supplementation arms evaluated separately: calcium alone (11 trials, 9,067 participants), vitamin D alone (36 trials, 92,045 participants), and combined calcium + vitamin D (15 trials, 51,126 participants). Primary outcomes: any fracture, hip fracture, falls. Evidence certainty rated using GRADE methodology. Authors are Canadian; article processing charges paid by CIUSSS du Nord-de-l'île-de-Montréal.
Key results:
| Supplement | Trials (n) | Evidence certainty | Effect on any fracture |
|---|---|---|---|
| Calcium alone | 11 (9,067 pts) | Moderate | No meaningful benefit |
| Vitamin D alone | 36 (92,045 pts) | High | No meaningful benefit |
| Calcium + vitamin D | 15 (51,126 pts) | High | No meaningful benefit |
No meaningful benefit was found for hip fracture or falls across any supplementation arm.3
The authors' conclusion: "These findings do not support routine supplementation with calcium or vitamin D, or combined supplementation to prevent fractures and falls."3
A linked BMJ editorial called for redirecting attention and funding toward interventions with established efficacy for fall prevention: balance training, resistance exercise, and individualized programs combining exercise with hazard assessment or education.3
Peer-review status: Published in The BMJ; fully peer-reviewed.
Clinical implication: Calcium and vitamin D supplementation for fracture prevention is one of the most widely recommended preventive interventions in older adult care. High-certainty evidence at this scale (36 trials for vitamin D alone) is a meaningful signal for guideline bodies — USPSTF, NICE, and endocrinology/geriatrics societies have varying current recommendations, and several already de-emphasized routine supplementation in community-dwelling adults without deficiency. The main take for clinicians: supplementation in the setting of documented deficiency is not addressed by this meta-analysis (those patients were not the focus); the evidence targets routine supplementation in the general older adult population. That distinction matters for patient counseling.
3. LOSE-AF: 10% weight loss doesn't reduce AF symptoms in older patients with persistent AF
Journal: JAMA (IF ~120) · Parallel-group unblinded RCT · Published online May 20, 2026 · DOI 10.1001/jama.2026.57874
Study design: Randomized clinical trial at two UK hospitals, November 2018 – April 2025. 118 participants (mean age 68 [SD 6]; 33% female; BMI ≥27; aged 60–85) with persistent atrial fibrillation (AF) randomized to an 8-month low-calorie diet plus behavioral support (n=59) vs. usual care (n=59). Primary endpoint: AF Symptom Severity (AFSS) score at 8 months. Pre-registered: NCT03713775.
Key results:
- Weight loss achieved: −6.9 kg in the intervention arm (92.6 kg vs. 99.4 kg; 95% CI −9.2 to −4.5; P<.001) — representing 9.7% vs. 3.1% body weight reduction4
- Primary endpoint (AFSS symptom severity): no significant difference (7.9 intervention vs. 8.9 control; between-group difference −0.9, 95% CI −3.3 to 1.4; P=.43)4
- No significant effects on AF burden, cardiac imaging parameters, blood pressure, lipid profile, or rates of repeat cardioversion or AF ablation
- No serious adverse events in either group
Peer-review status: Published in JAMA; fully peer-reviewed.
Author affiliation: Two UK hospitals; corresponding authors not confirmed in accessible records. JAMA Associate Editor Gregory M. Marcus, MD, MAS (University of California, San Francisco) provided an editorial noting that weight loss is already guideline-recommended in AF and remains important for overall health, but that LOSE-AF suggests different mechanisms may drive AF in older vs. younger populations.
Clinical implication: Prior AF research — including LEGACY and CARDIO-FIT — enrolled younger, more obese patients and found AF burden reduction with weight loss. The null result in LOSE-AF's older, less obese cohort (BMI ≥27, mean age 68) suggests a possible age-related mechanistic difference: hemodynamic and structural changes that drive persistent AF in older patients may be less reversible through weight change alone. Weight loss still carries broad cardiovascular and metabolic benefit; the finding doesn't reverse that recommendation. What it does caution against is using AF symptom improvement as a primary motivating rationale for weight loss interventions in older patients with persistent AF.
4. County-level structural racism independently predicts lung cancer care disparities
Journal: JAMA Network Open (IF ~13) · Cross-sectional study · Published May 20, 2026 · DOI [jamanetworkopen/fullarticle/2849161]5
Study design: Cross-sectional analysis of 54,344 older patients with lung cancer drawn from a national dataset: 10.3% Non-Hispanic Black (NHB), 89.7% Non-Hispanic White (NHW). Two structural racism measures used: a county-level deprivation index and a residential dissimilarity index. Outcomes: stage at diagnosis (localized vs. advanced), receipt of stage-appropriate evaluation and treatment, and 2-year survival. Adjusted for age, sex, marital status, year of diagnosis, comorbidity burden, prior hospitalizations, and frailty.5
Key results:
Non-Hispanic Black vs. Non-Hispanic White patients (adjusted):
- Localized-stage diagnosis: AOR 0.73 (95% CI 0.68–0.78; P<.001)5
- Stage-appropriate evaluation and treatment: AOR 0.71 (95% CI 0.65–0.76; P<.001)5
- 2-year survival: AOR 0.76 (95% CI 0.70–0.81; P<.001)5
Highest vs. lowest structural racism quintile (deprivation measure):
- Localized-stage diagnosis: AOR 0.84 (95% CI 0.74–0.94; P trend=.02)5
- Stage-appropriate treatment: AOR 0.69 (95% CI 0.59–0.80; P trend<.001)5
- 2-year survival: AOR 0.66 (95% CI 0.58–0.75; P trend<.001)5
A significant race × dissimilarity-index interaction was found for localized-stage diagnosis (P=.01) and 2-year survival (P=.002), indicating that the structural racism–outcome relationship differs by race.
Peer-review status: Published in JAMA Network Open; fully peer-reviewed.
Clinical implication: Prior disparities research has documented Black–White gaps in lung cancer outcomes but attributed much of the difference to individual-level factors (access to insurance, smoking history, comorbidities). This study isolates the county-level structural component: patients living in higher-deprivation counties face worse odds of localized diagnosis, appropriate treatment, and 2-year survival after individual-level confounders are accounted for. The 34% survival gap in the highest vs. lowest structural racism quintile is larger than the treatment-receipt gap — suggesting barriers operate at multiple points in the care pathway. For oncologists and health systems planners, the implication is that patient-level interventions alone won't close the disparity; the county-level environment in which care is delivered is itself a prognostic variable.
5. Isotretinoin in adolescence not associated with clinically meaningful height reduction
Journal: JAMA Dermatology (IF ~20) · Nationwide population-based cross-sectional study · Published online May 20, 2026 · DOI 10.1001/jamadermatol.2026.11976
Study design: Nationwide cohort from Denmark's military conscription registry, 2001–2015. 379,196 individuals eligible for conscription (median age 19.0 in men, 19.2 in women) with height measured at conscription. Isotretinoin users: 16,739 men and 278 women. Comparison groups: oral tetracycline users, topical acne therapy users, and no-treatment controls. Minimum clinically important difference (MCID) threshold for height: ≥5 cm. Median cumulative isotretinoin dose: 5,000 mg in men, 4,750 mg in women.6
Key results:
| Group | Adjusted mean height difference vs. comparators | Interpretation |
|---|---|---|
| Men (all ages) | +0.31 cm (95% CI 0.20–0.41) | Well below 5 cm MCID |
| Women | +0.25 cm (95% CI −0.47 to 0.96) | Well below 5 cm MCID |
| Men starting before age 13 | −1.70 cm (95% CI −3.15 to −0.25) | Statistically significant but still below 5 cm MCID |
No dose-response association was found.6 Isotretinoin-treated men were actually less likely to be classified as stunted than no-treatment controls (adjusted prevalence ratio 0.72, 95% CI 0.63–0.81; 1.51% vs. 2.14%).
Peer-review status: Published in JAMA Dermatology; fully peer-reviewed. Funded by Aage Bangs Foundation, Fonden til Laegevidenskabens Fremme, and the Health Research Foundation of Central Denmark Region.
Author affiliation: Lead author Sigrún Alba Jóhannesdóttir Schmidt, MD, PhD (Aarhus University, Denmark).
"These findings may provide reassurance for clinicians, patients, and families and support shared evidence-based decision-making when isotretinoin therapy is considered during adolescence."— Sigrún Alba Jóhannesdóttir Schmidt, Aarhus University6
Clinical implication: Concerns about isotretinoin's effect on skeletal growth have historically made clinicians and families hesitant to start therapy during early adolescence — a period when untreated severe acne carries substantial psychosocial burden. With 379,196 individuals and an objectively measured outcome (conscription height), this is the largest dataset yet brought to bear on the question. The observed differences are an order of magnitude below the 5 cm MCID and show no dose-response pattern, making a clinically meaningful growth-stunting effect implausible. The small but statistically significant −1.70 cm finding in boys starting before age 13 remains worth monitoring in prospective follow-up; it doesn't meet the MCID threshold but the confidence interval doesn't include zero.
References
- 1
- 2Arthritis Drug Rescues Hard-to-Treat Depression — Neuroscience News
neurosciencenews.com
- 3
- 4
- 5
- 6
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.